MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-12-2026
DexCom Revenue 2011-2026 | DXCM
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue DexCom
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.66 B | 4.03 B | 3.62 B | 2.91 B | 2.45 B | 1.93 B | 1.48 B | 1.03 B | 718 M | 573 M | 402 M | 259 M | 160 M | 99.9 M | 76.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.66 B | 76.3 M | 1.63 B |
Quarterly Revenue DexCom
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.16 B | 1.04 B | - | 994 M | 1 B | 921 M | - | 975 M | 871 M | 742 M | - | 770 M | 696 M | 629 M | - | 650 M | 595 M | 505 M | - | 501 M | 452 M | 405 M | 463 M | 396 M | 336 M | 280 M | 338 M | 267 M | 242 M | 184 M | 221 M | 185 M | 171 M | 142 M | 171 M | 149 M | 137 M | 116 M | 131 M | 105 M | 93.2 M | 72.8 M | 84.3 M | 69 M | 58.8 M | 47.1 M | 51.7 M | 42.9 M | 35.8 M | 29.6 M | 33.3 M | 23.1 M | 23.4 M | 20.1 M | 22.4 M | 18.3 M | 21.4 M | 14.2 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.16 B | 14.2 M | 334 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
5.31 M | $ 2.13 | - | $ 4.89 M |  USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 75.5 | -0.31 % | $ 5.1 B | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
6.81 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 455.28 | -0.36 % | $ 13.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 229.6 | -0.87 % | $ 25.3 B |  Schweiz |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 156.54 | -0.92 % | $ 7.76 B | USA |
 |
IQVIA Holdings
IQV
|
16.3 B | $ 165.42 | -0.95 % | $ 28.4 B | USA |
 |
Myriad Genetics
MYGN
|
824 M | $ 4.6 | -1.29 % | $ 426 M | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
28.5 M | $ 1.25 | -14.38 % | $ 6.81 M | USA |
 |
National Research Corporation
NRC
|
137 M | $ 17.47 | -0.26 % | $ 391 M | USA |
 |
Interpace Biosciences
IDXG
|
46.9 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
IDEXX Laboratories
IDXX
|
4.3 B | $ 569.86 | -1.5 % | $ 45.8 B | USA |
 |
Illumina
ILMN
|
4.37 B | $ 122.99 | -0.65 % | $ 19.6 B | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 100.22 | -0.13 % | $ 8.27 B |  Irlanda |
 |
Guardant Health
GH
|
982 M | $ 84.35 | -0.65 % | $ 10.6 B | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B |  Niderland |
 |
Pacific Biosciences of California
PACB
|
160 M | $ 1.38 | -1.08 % | $ 414 M | USA |
 |
Precipio
PRPO
|
15.2 M | $ 26.93 | - | $ 35 M | USA |
 |
Personalis
PSNL
|
84.6 M | $ 7.71 | 1.37 % | $ 457 M | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 263.52 | -0.36 % | $ 21.9 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
RadNet
RDNT
|
2.04 B | $ 60.39 | -2.19 % | $ 4.54 B | USA |
 |
ENDRA Life Sciences
NDRA
|
6.17 K | $ 3.41 | -2.16 % | $ 1.83 M | USA |
 |
NeoGenomics
NEO
|
727 M | $ 7.91 | -2.35 % | $ 1.01 B | USA |
 |
Agilent Technologies
A
|
6.32 B | $ 111.72 | -0.27 % | $ 34 B | USA |
 |
Natera
NTRA
|
820 M | $ 194.13 | -2.98 % | $ 19.1 B | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 17.24 | -1.82 % | $ 919 M | USA |
 |
OPKO Health
OPK
|
184 M | $ 1.14 | -0.88 % | $ 791 M | USA |
 |
Senseonics Holdings
SENS
|
35.3 M | $ 6.58 | -0.68 % | $ 275 M | USA |
 |
Castle Biosciences
CSTL
|
332 M | $ 25.84 | 0.35 % | $ 718 M | USA |
 |
Sotera Health Company
SHC
|
1.16 B | $ 13.77 | -0.79 % | $ 3.91 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 194.57 | -0.54 % | $ 21.6 B | USA |
 |
DarioHealth Corp.
DRIO
|
22.4 M | $ 7.37 | -1.73 % | $ 29.4 M | Israel |